Breaking

Teva Executives Sold Shares Worth About $3 Million

The interim chief legal officer and a senior vice president for international markets sold more than 72,000 shares of the pharmaceutical company, worth a combined total of about $3.02 million • The sales were reported to the U.S. Securities and Exchange Commission (SEC)

Teva Pharmaceutical Industries
Teva Pharmaceutical Industries | Photo: Shutterstock

Two executives at Teva (TEVA) sold company shares worth a combined total of about $3.02 million, according to filings submitted to the U.S. Securities and Exchange Commission (SEC).

According to the filings, Dov Bergwerk, who serves as an officer and the company’s interim chief legal officer, sold 26,260 ordinary shares at a price of $41.72 per share. The total proceeds from the sale amounted to about $1.1 million. Following the transaction, he directly owned 11,943 Teva shares.

At the same time, Mark Sabag, senior vice president for commercial operations in international markets, sold 46,000 shares at a weighted average price of about $41.93 per share. The transaction was worth about $1.93 million. Following the sale, he directly owned 80,760 company shares.

In total, the two executives sold 72,260 shares for about $3.02 million. Both transactions were reported using Form 4, which is used to report changes in the holdings of officers and interested parties in companies traded in the U.S.

It is important to note that share sales by executives do not necessarily indicate their assessment of the company’s future or an expectation that the stock will decline, and the transactions should also be examined in light of the sellers’ personal and financial circumstances.

Key takeaways

  • Two Teva executives sold a combined 72,260 shares for about $3.02 million, according to SEC filings.
  • Dov Bergwerk sold 26,260 ordinary shares at $41.72 per share and received about $1.1 million.
  • Mark Sabag sold 46,000 shares at a weighted average price of about $41.93 per share and received about $1.93 million.
  • After the transactions, Bergwerk directly owned 11,943 Teva shares and Sabag directly owned 80,760 shares.
  • The sales were reported on Form 4, which is used to disclose changes in holdings of company officers and interested parties.

Questions and answers

Who sold Teva shares in this filing?
Dov Bergwerk, Teva’s interim chief legal officer, and Mark Sabag, senior vice president for commercial operations in international markets, were the two sellers.
How many Teva shares were sold and for how much?
The two executives sold 72,260 shares in total for about $3.02 million. Bergwerk sold 26,260 shares and Sabag sold 46,000 shares.
Do executive share sales necessarily mean the stock will fall?
No. The article says share sales by executives do not necessarily indicate their view of the company’s future or an expectation that the stock will decline, and they should be considered alongside personal and financial circumstances.

Share this story

About the writer

TV10 Desk

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by TV10 Desk

More for you